ONWARD Medical N.V. (US ADR: ONWRY, Euronext: ONWD) regularly publishes news about its neurotechnology therapies for people with spinal cord injuries (SCI) and other movement disabilities. Company updates highlight progress with ARC Therapy, including the non-invasive ARC-EX® System and the investigational implantable ARC-IM® and ARC-BCI® platforms.
News items often cover commercial traction for the ARC-EX System, such as the number of systems sold to US clinics and the expansion of access across dozens of rehabilitation centers. Releases also describe regulatory developments, including FDA 510(k) clearance for ARC-EX, CE Mark certification in the European Union, and an Investigational Device Exemption (IDE) for ARC-IM that enables the Empower BP global pivotal study for blood pressure instability after SCI.
Another recurring theme in ONWARD Medical’s news flow is science and technology leadership. The company reports results from pivotal and feasibility studies like Up-LIFT and Pathfinder2, as well as landmark publications in journals such as Nature, Nature Medicine, and Neurology: Clinical Practice. These articles, as summarized in press releases, describe outcomes related to hand strength and sensation, quality of life, upper body function, and blood pressure regulation.
Investors following ONWRY news will also find announcements about capital raises, private placements on Euronext markets, and the use of proceeds to fund product development, clinical trials, regulatory activities, and commercialization of ARC-EX in the US, Europe, and selected other geographies. Coverage notes the participation of institutional and sector-focused investors and mentions equity research initiation by banks.
This news page aggregates these company communications so readers can review updates on clinical milestones, regulatory decisions, commercialization progress, and financing activities related to ONWARD Medical and its ARC Therapy platform.
ONWARD Medical (ONWRY) reported first half 2026 results with sharp growth in ARC-EX product revenue and continued investment in its ARC Therapy pipeline.
Total revenue and other income reached EUR 4.2M, with ARC-EX System sales rising from EUR 1.0M in H1 2025 to EUR 3.4M in H1 2026, a 240% increase. The company sold or supplied via paid evaluation 159 ARC-EX Systems, a 430% year-over-year increase in units, and expanded availability to over 130 US clinics plus initial home-use, including within the US Veterans Affairs community.
ONWARD recorded an operating loss of EUR 23.3M and a net loss of EUR 24.7M, reflecting higher operating expenses of EUR 26.3M as it scales commercialization and R&D. The company strengthened its balance sheet with a EUR 40.6M equity raise, including EUR 25M from EQT Life Sciences, and a new up to EUR 50M debt facility from BlackRock, ending H1 with cash of EUR 81.5M.
ONWARD Medical (ONWRY) will release its first-half 2026 financial results and provide a comprehensive business update via webcast on September 9, 2026. CEO Dave Marver will host the event starting at 2:00 p.m. CEST / 8:00 a.m. EDT, with registration required to join the live session.
A replay of the webcast and supporting materials will be available on the company’s investor relations site. ONWARD Medical develops its proprietary ARC Therapy and offers the ARC-EX external system, cleared for sale in the US and Europe, while also advancing investigational implantable and BCI-enabled systems for spinal cord injury and movement disabilities.
ONWARD Medical (ONWRY) reported the first implant in its EIGER clinical feasibility study of the investigational ARC-IM® System to restore mobility after spinal cord injury (SCI).
EIGER will assess the safety and preliminary effectiveness of ARC-IM to support recovery of standing and walking in up to 12 participants across two cohorts: people with subacute SCI (injury less than six weeks before enrollment) and people with chronic SCI (injury more than one year before enrollment). The study is being conducted at Schweizer Paraplegiker-Zentrum in Nottwil and Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, where the first procedure was performed under the direction of Dr. Jocelyne Bloch.
The ARC-IM System combines an implanted neurostimulator and a lumbar lead to activate spinal circuits involved in lower-limb and trunk movement. ONWARD is developing ARC-IM for multiple SCI-related and movement disorder indications and notes ARC-IM and ARC-BCI remain investigational, while its ARC-EX® System is commercially cleared in the US and Europe.
ONWARD Medical (OTC:ONWRY) reported Q1 2026 revenue of EUR 2.0 million, including EUR 1.3 million from ARC-EX sales. The company supplied 70 ARC-EX Systems and expanded availability to 100+ clinics. Cash was EUR 53.4 million, and an April equity raise of over EUR 40 million extended cash runway into Q1 2028.
Clinical progress included first enrollment and implant in the global pivotal Empower BP study for ARC-IM, additional ARC-IM use in Parkinson’s disease, and two more individuals receiving investigational ARC-BCI therapy.
ONWARD Medical (US ADR: ONWRY) will release its first quarter 2026 financial results on May 26, 2026 and host a webcast business update.
The webcast, presented by CEO Dave Marver, is scheduled for 2:00 PM CEST / 8:00 AM EDT, with replay and materials on ir.onwd.com.
ONWARD Medical (US ADR: ONWRY) reported that shareholders approved all proposed resolutions at its 2026 Annual General Meeting of Shareholders held on May 13, 2026, in Amsterdam.
The announcement is classified as inside information under EU rules. Full resolution details are available on the company’s investor relations website.
ONWARD Medical (OTC:ONWRY) announced the closing of a private placement with institutional investors, raising EUR 40.6M in gross proceeds on April 20, 2026. The new shares issued in the Private Placement are now admitted to listing and trading on Euronext Brussels, Amsterdam, and Paris.
The company noted the announcement contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
ONWARD Medical (OTC:ONWRY) raised EUR 40.6M via a private placement of 13,520,254 new shares at EUR 3.00 each, including a EUR 25.0M investment from EQT Life Sciences.
Net proceeds are allocated to ARC-IM® development (40%), ARC-EX® commercialization (30%), quality/admin (20%) and working capital/debt (10%), and are expected to extend cash runway into Q1 2028 assuming no drawdown of the company debt facility.
ONWARD Medical (OTC:ONWRY) launched a private placement to raise gross proceeds of approximately EUR 40 million, with EQT Life Sciences expected to invest EUR 25 million. The New Shares will be issued via bookbuild, excluding existing shareholders’ pre-emptive rights, and are expected to list on April 20, 2026.
Proceeds are allocated to ARC-IM development (40%), ARC-EX commercialization (30%), quality/administration (20%) and working capital/debt service (10%), and are expected to provide cash runway into Q1 2028 assuming no drawdown of the debt facility.
ONWARD Medical (US ADR: ONWRY) convened its 2026 Annual General Meeting of Shareholders to be held in Amsterdam on May 13, 2026, with record date April 15, 2026. Proposed resolutions include adoption of 2025 accounts, discharge of directors, appointment of EY Accountants B.V. as auditor, three director appointments, delegation to issue ordinary shares (up to 10% and up to 50% of issued capital), and authorization to acquire ordinary shares. AGM materials and the convening notice are available on the company website as of April 1, 2026. US ADR holders (ONWRY) will receive notice from Bank of New York Mellon.